News
OTLK
0.2222
-11.16%
-0.0279
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 1d ago
Regulatory Uncertainty and Data Limitations Justify Hold Rating and Constrained Upside for Outlook Therapeutics
TipRanks · 2d ago
FDA Accepts Outlook Therapeutics' FDRR To Resolve ONS-5010/LYTENAVA Regulatory Issues; Stock Up
NASDAQ · 2d ago
Outlook Therapeutics Pursues FDA Dispute Resolution for ONS-5010
TipRanks · 2d ago
Outlook Therapeutics Files FDA Resolution Request After Rejection For Vision Loss Drug
Benzinga · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Apple, Intel, Alignment Healthcare
Reuters · 2d ago
Outlook Therapeutics submits formal dispute resolution request to FDA
TipRanks · 2d ago
BUZZ-Outlook Therapeutics rises as FDA agrees to review eye drug decision
Reuters · 2d ago
OUTLOOK THERAPEUTICS INC - FDA ACCEPTS OUTLOOK THERAPEUTICS' DISPUTE RESOLUTION REQUEST FOR ONS-5010/LYTENAVA; MEETING IN APRIL 2026
Reuters · 2d ago
Weekly Report: what happened at OTLK last week (0330-0403)?
Weekly Report · 4d ago
Weekly Report: what happened at OTLK last week (0323-0327)?
Weekly Report · 03/30 09:57
Outlook Therapeutics Completes Dilutive Equity Offering With Warrants
TipRanks · 03/25 21:34
Outlook Therapeutics closes $5.0 million public offering; warrants target up to $5.0 million additional proceeds
Reuters · 03/25 20:06
OUTLOOK THERAPEUTICS ANNOUNCES CLOSING OF $5.0 MILLION PUBLIC OFFERING
Reuters · 03/25 20:05
Press Release: Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
Dow Jones · 03/25 20:05
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
Barchart · 03/25 15:05
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 03/24 17:05
BUZZ-U.S. STOCKS ON THE MOVE-FedEx, Estee Lauder, Janus Henderson
Reuters · 03/24 16:09
Crude Oil Gains Around 4%; US Business Activity Declines In March
Benzinga · 03/24 16:00
Dow Falls Over 350 Points; Core & Main Posts Mixed Q4 Results
Benzinga · 03/24 13:55
More
Webull provides a variety of real-time OTLK stock news. You can receive the latest news about Outlook Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About OTLK
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.